These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 14592887)

  • 1. T cells and cytokines in the pathogenesis of acquired myasthenia gravis.
    Milani M; Ostlie N; Wang W; Conti-Fine BM
    Ann N Y Acad Sci; 2003 Sep; 998():284-307. PubMed ID: 14592887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models of myasthenia gravis.
    Christadoss P; Poussin M; Deng C
    Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis.
    Ostlie NS; Karachunski PI; Wang W; Monfardini C; Kronenberg M; Conti-Fine BM
    J Immunol; 2001 Apr; 166(8):4853-62. PubMed ID: 11290761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The susceptibility to experimental myasthenia gravis of STAT6-/- and STAT4-/- BALB/c mice suggests a pathogenic role of Th1 cells.
    Wang W; Ostlie NS; Conti-Fine BM; Milani M
    J Immunol; 2004 Jan; 172(1):97-103. PubMed ID: 14688314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice.
    Karachunski PI; Ostlie NS; Monfardini C; Conti-Fine BM
    J Immunol; 2000 May; 164(10):5236-44. PubMed ID: 10799884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
    Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H
    Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.
    Wang W; Milani M; Ostlie N; Okita D; Agarwal RK; Caspi RR; Conti-Fine BM
    J Immunol; 2007 Jun; 178(11):7072-80. PubMed ID: 17513756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokines and the pathogenesis of myasthenia gravis.
    Zhang GX; Navikas V; Link H
    Muscle Nerve; 1997 May; 20(5):543-51. PubMed ID: 9140360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
    Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
    J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.
    Tüzün E; Allman W; Ulusoy C; Yang H; Christadoss P
    Ann N Y Acad Sci; 2012 Dec; 1274():133-9. PubMed ID: 23252908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
    Baggi F; Antozzi C; Toscani C; Cordiglieri C
    Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice.
    Balasa B; Deng C; Lee J; Bradley LM; Dalton DK; Christadoss P; Sarvetnick N
    J Exp Med; 1997 Aug; 186(3):385-91. PubMed ID: 9236190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.
    Balasa B; Deng C; Lee J; Christadoss P; Sarvetnick N
    J Immunol; 1998 Sep; 161(6):2856-62. PubMed ID: 9743346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
    Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
    Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis.
    Wang HB; Li H; Shi FD; Chambers BJ; Link H; Ljunggren HG
    Int Immunol; 2000 Oct; 12(10):1381-8. PubMed ID: 11007755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
    Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
    Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular myasthenia gravis induced by human acetylcholine receptor ϵ subunit immunization in HLA DR3 transgenic mice.
    Wu X; Tuzun E; Saini SS; Wang J; Li J; Aguilera-Aguirre L; Huda R; Christadoss P
    Immunol Lett; 2015 Dec; 168(2):306-12. PubMed ID: 26493475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement and cytokine based therapeutic strategies in myasthenia gravis.
    Tüzün E; Huda R; Christadoss P
    J Autoimmun; 2011 Sep; 37(2):136-43. PubMed ID: 21636248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis.
    Conti-Fine BM; Milani M; Wang W
    Ann N Y Acad Sci; 2008; 1132():193-209. PubMed ID: 18567869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-bet deficiency decreases susceptibility to experimental myasthenia gravis.
    Liu R; Hao J; Dayao CS; Shi FD; Campagnolo DI
    Exp Neurol; 2009 Dec; 220(2):366-73. PubMed ID: 19818352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.